Strategic Focus Coya Therapeutics is a clinical-stage biotechnology company concentrated on regulatory T cell biology to address systemic and neuroinflammation across neurodegenerative, autoimmune, and metabolic diseases, presenting multiple collaboration and licensing opportunities around Treg-enhancing biologics, exosomes, and autologous Treg therapies.

Product Pipeline Their COYA 301 and COYA 302 candidate programs target Treg function and numbers with distinct administration routes and combination approaches that may appeal to partners seeking synergistic anti-inflammatory therapies and potential expansion into related neurodegenerative conditions.

Clinical & Trials Active focus on expanding lead program COYA 302 beyond ALS to frontotemporal dementia and Parkinson’s disease, signaling potential for multi-indication collaborations, co-development deals, and shared trial infrastructure with biotech or pharma partners.

Market & Funding With revenue in the low millions and ongoing robust funding, Coya presents a growth-ready profile for strategic investors and larger biopharma seeking early-stage immunomodulatory assets, while readiness for partnering on late-stage milestones could be explored.

Engagement & Events Active outreach through conferences and scientific leadership, including Nobel Prize–related alignment with regulatory T cell expertise, offering multiple touchpoints for BD outreach, speaker engagements, and early collaboration discussions with potential licensors or developers.